Tempus AI (TEM)

The company works with clinical, molecular, imaging, and other real-world healthcare data, with a particular emphasis on precision medicine. By combining laboratory services, data analytics, and software tools, Tempus aims to help clinicians better understand a patient’s disease and support more individualized treatment decisions. Its intelligent diagnostics business includes genomic testing and related products that use AI, including generative AI techniques, to interpret complex datasets and improve the relevance of test results.

Tempus is best known for its role in oncology, where molecular profiling can guide therapy selection and clinical trial matching, but its platform is built to support broader use cases across disease areas. The company also serves biopharmaceutical partners by providing data-driven insights that can inform research, patient identification, and drug development strategies.

For investors, Tempus represents exposure to the intersection of healthcare data, diagnostics, and applied AI. Its business depends on the continued adoption of precision medicine, demand for advanced testing, and the ability to turn healthcare information into actionable insights while operating in a regulated medical environment.